サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：神経血管塞栓装置の世界市場-2023年～2030年
市場調査レポート
商品コード
1345458

神経血管塞栓装置の世界市場-2023年～2030年

Global Neurovascular Embolization Devices Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
神経血管塞栓装置の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

神経血管塞栓装置の世界市場は、2022年に37億米ドルに達し、2023年から2030年にかけてCAGR 6.4％で成長し、2030年には60億米ドルに達すると予測されています。

神経血管塞栓装置は、望ましくない血管奇形への血流を遮断・停止します。動脈瘤クリップ、液体塞栓システム、流路転換ステント、塞栓コイル、血管内流路破壊装置などが神経血管塞栓装置の例です。脳卒中とは、脳への血液供給が途絶え、酸素不足、脳損傷、機能不全に陥る病気です。

多くの場合、脳に血液を送る動脈の血栓が原因です。血管が破裂して血液が脳に滴下する出血によって誘発されることもあります。脳卒中は、部分的な麻痺や語彙力、認知力、記憶力の障害など、永続的な障害を引き起こす可能性があります。脳のどの部位が侵され、どの期間血液の供給が遮断されたかは、障害の種類と程度に影響します。

脳卒中や動脈瘤の症例の増加、製品認可の増加、研究活動からの好結果、M&Aを含む市場開拓、製品のイントロダクション、その他の要因の中でも認知度の向上が、予測期間における世界の神経血管塞栓装置市場の成長を後押しすると予想されます。さらに、症例の増加や研究資金の拠出も、予測期間における世界市場の成長に貢献すると期待されています。

ダイナミクス

脳卒中と動脈瘤の症例増加

脳卒中や動脈瘤の症例の増加は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、世界脳卒中機構によると、脳卒中はすでに流行の兆しを見せています。世界では、25歳以上の成人の4人に1人が一生のうちに脳卒中にかかると予想され、世界全体で1,220万人以上が今年初めて脳卒中にかかり、650万人がその結果として死亡すると予想されています。

全世界で1億1,000万人以上の人々が、現在に至るまで脳卒中に遭遇しています。脳卒中の有病率は年齢とともに大きく上昇しますが、それでも脳卒中の60％以上が70歳未満で発症し、50歳未満では約16％が発症しています。また、NHSイングランドによると、イングランドでは毎年12,500人のうち約1人が脳動脈瘤の破裂に罹患しています。

さらに、脳動脈瘤は英国ではおよそ3.0％の人に影響を及ぼし、脳動脈瘤財団は毎年600万人以上の米国人が脳動脈瘤の影響を受けていると評価しています。また、NIHによると、脳動脈瘤の世界の割合はおよそ3.2％で、標準年齢は50歳、男女比は1：1です。この比率は50歳を過ぎると大きく変化し、女性優位の比率が2：1になります。これは、循環エストロゲンの減少が血管組織のコラーゲン範囲の減少を引き起こすためと考えられています。

市場開発の拡大

世界の神経血管塞栓装置市場における開発の拡大は、世界市場を押し上げると期待されています。例えば、2021年7月、神経・末梢血管インターベンション医療機器企業であるZylox-Tonbridge Medical Technology Co., Ltd.は、神経血管塞栓用コイル、コイリング用マイクロカテーテルなどを含む中核開発の設計と商業化を維持するために3億2,900万米ドルを確保しました。さらに、2023年1月、Fluidx Medical Technology, Inc.は、脳表面の慢性硬膜下血腫（CSDH）の治療に利用できる中髄膜動脈（MMA）塞栓に関連する生体内調査でのIMPASS Embolic Deviceの成功に関するデータを開示しました。

同様に、2021年3月には、心臓血管および神経血管市場向けの革新的な治療法を開発するシェイプ・メモリー・メディカル社が、生分解性末梢血管塞栓用プラグのIMPEDEポートフォリオに追加されるIMPEDE-FX RapidFill DeviceのCEマーク承認を取得しました。さらに、2023年7月、シェイプ・メモリー・メディカル社は、世界の医療技術市場のリーダーとサブライセンス契約を締結しました。この契約により、シェイプ・メモリー・メディカル社は、シェイプ・メモリー・メディカル社が注力している心臓血管、血管内、神経血管以外の治療分野における狭い適応症に対して、独自の形状記憶ポリマー技術をサブライセンスし、契約一時金と将来のランドマークおよびロイヤルティを得る予定です。

製品回収

安全性の懸念による製品回収は、予測期間中の世界市場の成長を妨げると予想されます。例えば、2021年9月、メドトロニックは、脳動脈瘤を塞ぐために利用される経カテーテルデバイスであるパイプラインフレックス塞栓デバイスおよびシールド技術付きパイプラインフレックス塞栓デバイスをリコールしました。同社は、ステントを患者の体内で位置決めしたり、回収したり、押し込んだりする際に、送達システムのワイヤーやチューブが破断したり、折れたりする危険性があると表明しました。

FDAはこれをクラスiのリコールと認定しました。これらの機器の使用は、深刻な損傷または死亡を引き起こすと推定されます。このリコールに関連して記録された機器の不具合は59件、深刻な損害は10件、死亡は2件です。このリコールは、2019年4月から2020年8月の間に流通した米国内の8,825台の機器を対象としています。メドトロニック社は、デバイスを製造するマイクロ・セラピューティクス社、ev3ニューロバスキュラー社の親会社グループです。2021年7月に全購入者にリコール文書が郵送され、影響を受けた製品の使用を中止し、未使用の影響を受けた製品を直ちに隔離するよう求められました。

高額なデバイスと平均入院費用

神経血管塞栓装置の高額な費用と平均入院費は、予測期間における世界市場の成長を鈍化させると予想されます。例えば、Journal of Vascular Surgery誌に掲載された研究によると、頭蓋内動脈瘤塞栓術に使用されるコイルの価格は、市場における競合の増加にもかかわらず上昇し続けています。米国市場におけるコイルの定価は500～3000米ドルです。

平均的な治療費は21,687.22米ドルであり、動脈瘤の部位によって多少の差があります。さらに、血管内大動脈瘤修復術の平均入院費用は45,304米ドルでした（50％の手術室消耗品、グラフトを含む）。動脈瘤に関連した再入院と再インターベンションの平均費用はそれぞれ13,119米ドルと22,023米ドルでした。外来患者への支払いは1人当たり年平均657米ドルで、その72％はコンピューター断層撮影によるものでした。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品承認の増加と前向きな調査結果
      • 各団体による取り組みの増加
    • 抑制要因
      • 神経血管塞栓装置の高額の治療費
      • 疾患の有病率の低さ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • 技術動向
  • エンドユーザー動向
  • SWOT分析
  • DMIの見解

第6章 COVID-19分析

第7章 製品タイプ別

  • 液体塞栓システム
  • 塞栓用コイル
  • 動脈瘤クリップ
  • 流路迂回ステント
  • その他

第8章 治療薬別

  • 経口虚血性脳卒中治療薬
  • 出血性脳卒中治療薬

第9章 適応症別

  • 乳幼児脳動脈瘤
  • 動静脈奇形
  • その他

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • 学術研究センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Medtronic plc
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Stryker Corporation
  • Johnson & Johnson Inc.
  • Terumo Corporation
  • B. Braun Melsungen AG.
  • Integra LifeSciences Corporation
  • Acandis GmBH
  • Phenox GmBH
  • Lepu Medical Technology（Beijing）Co.
  • Shape Memory Medical Inc.

第14章 付録

目次
Product Code: MD6816

Overview

Global Neurovascular Embolization Devices Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 6.0 billion by 2030, growing with a CAGR of 6.4% during the forecast period 2023-2030.

Neurovascular embolization devices block or stop blood flow to undesirable vessel malformations. Aneurysm clips, liquid embolic systems, flow diversion stents, embolization coils, and intravascular flow disruptors are examples of neurovascular embolization devices. Stroke is an ailment where the blood supply to the brain is disrupted, resulting in a lack of oxygen, brain injury, and failure to perform.

It is most often because of a clot in an artery delivering blood to the brain. It can even be induced by hemorrhage when a burst vessel leads blood to drip into the brain. Stroke can induce enduring injury, such as partial paralysis and impairment in vocabulary, cognition, and remembering. The region of the brain involved and the period the blood supply has been blocked affects the sort and severity of disability.

The growing cases of brain stroke and aneurysms, increasing product authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global neurovascular embolization devices market growth in the forecast period. Further, the growing cases and research fundings are also expected to contribute to the global market growth in the forecast period.

Dynamics

Growing Cases of Brain Stroke and Aneurysms

The growing cases of brain stroke and aneurysms are expected to boost the global market growth during the forecast period. For instance, according to the World Stroke Organization, stroke has already achieved epidemic ratios. Worldwide 1 out of 4 adults above the age of 25 are expected to have a stroke in their lifetime, over 12.2 million individuals globally are anticipated to encounter their first stroke this year and 6.5 million will die as a consequence.

More than 110 million individuals in the globe have encountered a stroke till present in their lives. The prevalence of stroke rises greatly with age, nevertheless, more than 60% of strokes transpire to individuals under the age of 70, and around 16% transpire to those below the age of 50. Moreover, according to the NHS England, about 1 out of 12,500 individuals in England have a ruptured brain aneurysm every year.

Furthermore, brain aneurysm impacts roughly 3.0% of people in the U.K. and the Brain Aneurysm Foundation assesses that over 6.0 million Americans are affected by brain aneurysms annually. In addition, according to the NIH, the global preponderance of cerebral aneurysms is roughly 3.2%, with a standard age of 50 and an altogether 1:1 gender ratio. This ratio varies greatly after age 50, with an increasing female predominance closing 2:1, considered to be owing to reduced circulating estrogen inducing a decrease in the collagen range of the vascular tissue.

Increasing Market Developments

The increasing market developments in the global neurovascular embolization devices market are expected to boost the global market. For instance, in July 2021, Zylox-Tonbridge Medical Technology Co., Ltd., a neuro- and peripheral-vascular interventional medical device corporation secured USD 329 million to sustain the designing and commercialization of its core developments including neurovascular embolization coils, a microcatheter for coiling, among others. Moreover, in January 2023, Fluidx Medical Technology, Inc., disclosed the data concerning the success of the IMPASS Embolic Device in in-vivo research associated with middle meningeal artery (MMA) embolizations which can be utilized for the treatment of chronic subdural hematomas (CSDH) on the surface of the brain.

Similarly, in March 2021, Shape Memory Medical Inc., a designer of innovative treatments for cardiovascular and neurovascular markets, obtained CE Mark Approval for the IMPEDE-FX RapidFill Device, an addition to the IMPEDE portfolio of biodegradable peripheral vascular embolization plugs. Further, in July 2023, Shape Memory Medical Inc. formed a sublicense deal with a global MedTech market leader. Under this, Shape Memory Medical intends to sublicense its proprietary shape memory polymer technology for a narrow indication in a therapeutic area beyond Shape Memory Medical's cardiovascular, endovascular, and neurovascular focus, in retrieval for an upfront license fee, and future landmarks and royalties.

Product Recalls

The product recalls from the market due to safety concerns are expected to hamper the global market growth during the forecast period. For instance, in September 2021, Medtronic recalled its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology, which are transcatheter devices utilized to plug brain aneurysms. The corporation expressed a risk of the delivery system's wire and tubes fracturing and breaking off when the system is being utilized to position, recover, or push the stent inside a patient.

The FDA has recognized this as a Class I recall, the most severe type of recall. Usage of these devices is estimated to induce severe damage or death. There have been 59 documented device malfunctions, 10 severe damages, and two deaths linked to this recall. The recall encloses 8,825 devices in the United States that were distributed between April 2019 to August 2020. Medtronic is the parent group of Micro Therapeutics Inc., ev3 Neurovascular, which constructs the devices. A recall letter was mailed to all buyers in July 2021, asking them to stop the use of any impacted product and quarantine all unused impacted products immediately.

High Device and Mean Hospitalization Costs

The high neurovascular embolization devices costs and mean hospitalization costs are expected to slow the global market growth in the forecast period. For instance, according to a study published in the Journal of Vascular Surgery, the price of coils used for intracranial aneurysm embolization has continued to rise despite an increase in competition in the marketplace. Coils on the US market range in list price from $500 to $3000.

The average intervention cost was USD 21,687.22, with some variation according to the aneurysm site. Moreover, the mean hospitalization cost for endovascular aortic aneurysm repair was $45,304 (50% operating room supplies, including graft). The average aneurysm-related readmission and reintervention costs were $13,119 and $22,023, respectively. Outpatient payments averaged $657 per person per year, 72% of which is attributable to computed tomography scans.

Segment Analysis

The global neurovascular embolization devices market is segmented based on product type, treatment, indication, end-user and region.

Flow Diversion Stents Product Type Expected to Dominate Market

Owing to the increasing market developments in the Flow Diversion Stents segment it is expected to dominate the global market. For instance, in October 2022, the Medtronic Neurovascular Co-Lab Platform was designed to sustain the pace of much-required innovation in stroke treatment and sustenance. Their community platform strives to modify opinions and technology into breakthrough multinational treatments by providing entrepreneurs and medics understanding and consideration and, most significantly, ensuring that innovation arrives to as many individuals as imaginable around the globe.

Moreover, in January 2023, Therma Bright Inc. financed Israeli Ischemic Stroke Blood Clot Retriever Technologies Startup Inretio Inc. The PREVA basket "ensnares" the clot, enclosing it and shielding the brain from any sub-clots that break off in the thrombectomy therapy. Again, in February 2022, Perfuze, a company involved in designing next-generation catheter-based aspiration technology, secured a USD 23.94 million Series A financing round.

Geographical Penetration

Growing Cases of Stroke and Aneurysm

The increasing cases of stroke and aneurysms in North America are expected to boost the regional market growth, dominating the global market throughout the forecast period. For instance, according to CDC facts revised in 2022, each year over 795,000 individuals in the United States encounter a stroke, approximately 610,000 of these are first or new strokes. Moreover, in the United States, there is assessed to be at least one stroke every 40 seconds, and every four minutes, an individual dies of a stroke. The same source even noted that roughly 87% of all strokes are ischemic strokes, in which blood flow to the brain gets blocked. An assessed 6.7 million individuals in the United States have an unruptured brain aneurysm or 1 in 50 individuals, the yearly rate of rupture is around 8 - 10 per 100,000 individuals.

Further, almost 30,000 individuals in the United States encounter a brain aneurysm rupture annually, it is estimated that a brain aneurysm ruptures every 18 minutes. Furthermore, the increase in the research funding in this region are also expected to contribute to the regional market growth in the forecast period. For instance, in October 2021, the Udall Center at the University of Minnesota Medical School acquired a new USD 11.3 million funding from the National Institute of Neurological Stroke for research purposes.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Additionally, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

The COVID-19 pandemic induced substantial disruption to specified care pathways, including critical conditions including aneurysmal subarachnoid hemorrhage (SAH) (aSAH). There was a relative decrease in the number of patients with aSAH during the COVID-19 pandemic. In spite of the extremely different states of hospitalization, there was no impairing noteworthy impact on the treatment and consequence of admitted individuals with aSAH. A past COVID-19 infection appeared to be an unrelated determining factor affecting favorable results.

By Product Type

  • Liquid Embolic Systems
  • Embolization Coils
  • Aneurysm Clips
  • Flow Diversion Stents
  • Others

By Treatment

  • Ischemic Stroke Solutions
  • Hemorrhagic Stroke Solutions
  • Indication
    • Brain aneurysm
    • Arteriovenous malformations
    • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Academic Research Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In February 2023, Shape Memory Medical Inc., designer of shape memory polymer for peripheral and neurovascular markets, reported the first patient treated in Germany as component of the EMBO-Post Market Surveillance Registry, the Company's forthcoming, multicenter, registry investigation of its IMPEDE and IMPEDE-FX Embolization Plugs when used for peripheral vascular embolization.
  • In 2022, Rapid Medical, a designer of novel neurovascular devices, obtained FDA 510(k) authorization for TIGERTRIEVER 13 for the major vessel occlusions during the 19th Annual Conference of the Society of Neurointerventional Surgery (SNIS) in Toronto.
  • In June 2022, Medtronic introduced the CE-marked fourth generation flow system, pipeline vantage with Shield technology, for endovascular treatment of brain aneurysms.

Competitive Landscape

The major global players in the market include: Medtronic plc, Stryker Corporation, Johnson & Johnson Inc., Terumo Corporation, B. Braun Melsungen AG., Integra LifeSciences Corporation, Acandis GmBH, Phenox GmBH, Lepu Medical Technology (Beijing)Co., and Shape Memory Medical Inc. among others.

Why Purchase the Report?

  • To visualize the global neurovascular embolization devices market segmentation based on product type, treatment, indication, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of neurovascular embolization devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global neurovascular embolization devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Indication
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Approvals and Positive Research Outcomes
      • 4.1.1.2. Increasing Efforts from Distinct Associations
    • 4.1.2. Restraints
      • 4.1.2.1. High Treatment Cost of Neurovascular Embolization Devices
      • 4.1.2.2. Low Prevalence of the Disorder
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Technology Trend
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Liquid Embolic Systems*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Embolization Coils
  • 7.4. Aneurysm Clips
  • 7.5. Flow Diversion Stents
  • 7.6. Others

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Oral Ischemic Stroke Solutions*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hemorrhagic Stroke Solutions

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication
  • 9.2. Infants Brain aneurysm*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Arteriovenous malformations
  • 9.4. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Academic Research Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Medtronic plc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Stryker Corporation
  • 13.3. Johnson & Johnson Inc.
  • 13.4. Terumo Corporation
  • 13.5. B. Braun Melsungen AG.
  • 13.6. Integra LifeSciences Corporation
  • 13.7. Acandis GmBH
  • 13.8. Phenox GmBH
  • 13.9. Lepu Medical Technology (Beijing)Co.
  • 13.10. Shape Memory Medical Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us